Novel spectrometry market seen reaching $6.97 billion by 2030

The Business Research Company says the novel spectrometry market will grow from $5.15 billion in 2026 to $6.97 billion by 2030, driven by demand in pharmaceuticals, environmental monitoring and personalized medicine. North America was the largest regional market in 2025 as the sector gains from automation, portable instruments and AI-based data analysis.

Why it matters: - Novel spectrometry is gaining ground in pharmaceuticals, environmental science, forensic analysis and food safety testing. - The market’s forecast growth points to wider use of advanced analytical tools across regulated and research-heavy industries. - Personalized medicine is becoming a major demand driver because it depends on highly accurate biomarker analysis.

What happened: - The Business Research Company released its "Novel spectrometry Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035." - The report estimates the market will increase from $4.76 billion in 2025 to $5.15 billion in 2026. - The report forecasts the market will reach $6.97 billion by 2030. - The forecast implies a 7.9% compound annual growth rate from 2026 to 2030. - North America was the largest regional market in 2025. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - A free sample of the report is available here. - The full report is available here.

The details: - The market’s recent growth has been supported by pharmaceutical quality control, tighter environmental monitoring rules, broader mass spectrometry use in forensics, food safety testing demand and investment from academic and research labs. - Forecast growth is expected to come from automated analytical labs, portable spectrometry instruments, personalized medicine research, industrial process analytics and funding for advanced materials science. - Emerging trends include AI-enhanced spectral data interpretation, integration with smart factory systems, connected and remote spectrometry platforms, cloud-based spectral data management and precision-medicine analytics. - Novel spectrometry refers to advanced methods within spectrometry that improve the measurement and analysis of substance properties. - The report says these methods often use new technologies, instruments or analytical approaches to improve accuracy and efficiency. - Personalized medicine has accelerated because of advances in genomics. - In February 2024, the Personalized Medicine Coalition reported that the U.S. Food and Drug Administration approved 16 new personalized treatments for rare diseases in 2023, more than double the six approvals in 2022.

Between the lines: - The report signals a shift from traditional lab workflows toward more automated, connected and data-driven spectrometry systems. - North America’s lead suggests the market is being shaped by advanced research infrastructure and heavy demand from regulated industries. - The emphasis on AI, cloud tools and portable instruments suggests vendors are competing on speed, mobility and easier data handling, not just analytical precision.

What's next: - The report expects continued expansion through 2030 as personalized medicine and advanced analytics broaden the market’s use cases. - The company also says its 2026 reports add market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel dashboards, market hotspot infographics, key technologies and updated graphics and tables. - The Business Research Company lists Saumya Sahay as a contact for expert inquiries, with regional phone numbers and marketing@tbrc.info.

The bottom line: - Novel spectrometry is moving from a specialized analytical tool to a broader technology platform tied to healthcare, environmental compliance and automation.